HUP0202424A2 - Benzazepin-N-ecetsav származékokat tartalmazó oxidatív-toxikus, elsősorban kardiotoxikus anyagok ellen védőhatást kifejtő gyógyszerkészítmény - Google Patents

Benzazepin-N-ecetsav származékokat tartalmazó oxidatív-toxikus, elsősorban kardiotoxikus anyagok ellen védőhatást kifejtő gyógyszerkészítmény

Info

Publication number
HUP0202424A2
HUP0202424A2 HU0202424A HUP0202424A HUP0202424A2 HU P0202424 A2 HUP0202424 A2 HU P0202424A2 HU 0202424 A HU0202424 A HU 0202424A HU P0202424 A HUP0202424 A HU P0202424A HU P0202424 A2 HUP0202424 A2 HU P0202424A2
Authority
HU
Hungary
Prior art keywords
acetic acid
acid derivatives
medicament
protective effect
treatment
Prior art date
Application number
HU0202424A
Other languages
English (en)
Inventor
Julius Gy. Papp
Zsuzsanna Rózsa
Dirk Thormählen
Harald Waldeck
Original Assignee
Solvay Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh
Publication of HUP0202424A2 publication Critical patent/HUP0202424A2/hu
Publication of HUP0202424A3 publication Critical patent/HUP0202424A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A nitrogénatomhoz viszonyított a-helyzetben oxocsoportot tartalmazó ésa 3-helyzetben 1-(karboxi-alkil)-ciklopentil-karbonil-amino-csoporttal helyettesített benzazepin-N-ecetsav-származékok, valamintsóik és biolabilis észtereik a szívnek gyógyszerek vagy vegyi anyagokkardiotoxikus dózisai által okozott károsodásai megelőzésére és/vagykezelésére alkalmazhatók. A találmány különösen a szívnek - különösena szívizomnak - citosztatikus kemoterápia következtében fellépőkárosodásainak megelőzésére és/vagy kezelésére vonatkozik. A fentibenzazepin-N-ecetsav-származékok továbbá adjuváns kezelésrealkalmazhatók olyan terápiák keretein belül, amelyeknél oxidatív-toxikus mellékhatásokat mutató gyógyszereket használnak. A fentimegelőzésekre és/vagy kezelésekre, illetve adjuváns kezelésre alkalmasgyógyászati készítmények előállítása szintén a szabadalom tárgyátképezi. Ó
HU0202424A 1999-07-13 2000-07-10 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances containing benzazepine-n-acetic acid derivatives HUP0202424A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19932555A DE19932555A1 (de) 1999-07-13 1999-07-13 Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen

Publications (2)

Publication Number Publication Date
HUP0202424A2 true HUP0202424A2 (hu) 2002-11-28
HUP0202424A3 HUP0202424A3 (en) 2003-03-28

Family

ID=7914519

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202424A HUP0202424A3 (en) 1999-07-13 2000-07-10 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances containing benzazepine-n-acetic acid derivatives

Country Status (28)

Country Link
US (1) US6906059B2 (hu)
EP (1) EP1200095B1 (hu)
JP (1) JP4824235B2 (hu)
KR (1) KR100738940B1 (hu)
CN (1) CN1267099C (hu)
AR (1) AR024476A1 (hu)
AT (1) ATE306926T1 (hu)
AU (1) AU782733B2 (hu)
BR (1) BR0012442A (hu)
CA (1) CA2377904C (hu)
CZ (1) CZ299070B6 (hu)
DE (2) DE19932555A1 (hu)
DK (1) DK1200095T3 (hu)
ES (1) ES2246874T3 (hu)
HK (1) HK1049116B (hu)
HU (1) HUP0202424A3 (hu)
IL (2) IL147604A0 (hu)
MX (1) MXPA02000411A (hu)
NO (1) NO329558B1 (hu)
NZ (1) NZ517130A (hu)
PL (1) PL198723B1 (hu)
RU (1) RU2268727C2 (hu)
SK (1) SK286020B6 (hu)
TR (1) TR200200053T2 (hu)
TW (1) TWI280880B (hu)
UA (1) UA73134C2 (hu)
WO (1) WO2001003699A1 (hu)
ZA (1) ZA200200265B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
BR0209855A (pt) * 2001-05-18 2004-06-15 Solvay Pharm Gmbh Uso de compostos com atividade inibidora de nep/mp combinada na preparação de medicamentos
DE60234952D1 (de) * 2001-09-10 2010-02-11 Tibotec Pharm Ltd VERFAHREN ZUR HERSTELLUNG VON HEXAHYDROFUROc2,3-BÜFURAN-3-OL
RU2303041C2 (ru) * 2002-01-16 2007-07-20 Солвей Фармасьютикалс Б.В. Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
JP4824573B2 (ja) 2003-11-18 2011-11-30 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 腎不全、腎疾患または腎障害、特に糖尿病患者におけるこれらの治療のための医薬組成物
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
EP1827448A1 (en) 2004-12-15 2007-09-05 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
CA2643846A1 (en) * 2006-02-27 2007-09-07 Targeted Molecular Diagnostics, Llc Methods for predicting cellular toxicity upon treatment with tyrosine kinase inhibitors
WO2007102171A2 (en) * 2006-03-07 2007-09-13 Panacea Biotec Ltd Novel salts of 1h-1-benzazepine-1-acetic acid, their preparation and pharmaceutical composition
US20070292503A1 (en) * 2006-06-16 2007-12-20 Gorissen Henricus R Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) * 2006-06-22 2007-12-27 Rajesh Jain Oral pharmaceutical composition of a poorly water-soluble active agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
WO1999013871A2 (en) * 1997-09-18 1999-03-25 Janssen Pharmaceutica N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen

Also Published As

Publication number Publication date
ZA200200265B (en) 2003-03-26
TWI280880B (en) 2007-05-11
DE19932555A1 (de) 2001-01-18
CA2377904A1 (en) 2001-01-18
HK1049116B (zh) 2006-12-08
HK1049116A1 (en) 2003-05-02
KR20020019514A (ko) 2002-03-12
AU782733B2 (en) 2005-08-25
HUP0202424A3 (en) 2003-03-28
US20030040512A1 (en) 2003-02-27
DK1200095T3 (da) 2005-11-14
KR100738940B1 (ko) 2007-07-12
WO2001003699A1 (de) 2001-01-18
EP1200095A1 (de) 2002-05-02
ES2246874T3 (es) 2006-03-01
JP4824235B2 (ja) 2011-11-30
DE50011388D1 (de) 2006-03-02
CA2377904C (en) 2009-03-24
NO20020132L (no) 2002-03-12
TR200200053T2 (tr) 2002-05-21
CN1267099C (zh) 2006-08-02
MXPA02000411A (es) 2002-07-02
AR024476A1 (es) 2002-10-02
NO329558B1 (no) 2010-11-15
US6906059B2 (en) 2005-06-14
NZ517130A (en) 2004-10-29
CZ200252A3 (cs) 2002-08-14
EP1200095B1 (de) 2005-10-19
UA73134C2 (en) 2005-06-15
ATE306926T1 (de) 2005-11-15
PL198723B1 (pl) 2008-07-31
CZ299070B6 (cs) 2008-04-16
SK286020B6 (sk) 2008-01-07
CN1373666A (zh) 2002-10-09
NO20020132D0 (no) 2002-01-11
PL353012A1 (en) 2003-10-06
IL147604A0 (en) 2002-08-14
IL147604A (en) 2006-12-31
AU6157200A (en) 2001-01-30
RU2268727C2 (ru) 2006-01-27
SK142002A3 (en) 2002-06-04
JP2003504336A (ja) 2003-02-04
BR0012442A (pt) 2002-04-02

Similar Documents

Publication Publication Date Title
HUP0202424A2 (hu) Benzazepin-N-ecetsav származékokat tartalmazó oxidatív-toxikus, elsősorban kardiotoxikus anyagok ellen védőhatást kifejtő gyógyszerkészítmény
LU92642I2 (fr) Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid)
CY1107813T1 (el) Σακχαρικα παραγωγα υδρομορφονης, διϋδρομορφινης και διϋδροïσομορφινης συνθεσεις αυτων και χρησεις στην αποτροπη ή στην αγωγη εναντι του αλγους
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
NZ602675A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
ECSP045301A (es) Uso de derivado de indolopirrolocarbazol y otro agente anticancerosos en combinacion
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
NO20073403L (no) Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
CO2022005999A2 (es) Inhibidores del factor d del complemento para administración oral
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
CO2022005926A2 (es) Inhibidores del factor d del complemento para administración oral
MX2023012120A (es) Inhibidores heteroaromaticos biciclicos de la klk5.
ECSP056190A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
DE60111622D1 (de) Getrennte dosis therapien mit gefässschädigender aktivität
DK1231908T3 (da) Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf
HUP0301026A2 (hu) Arginin alkalmazása gyógyszer előállításában a gyógyszerek intravénás beadásával társuló mellékhatások megelőzésére és kezelésére
DE60214412D1 (de) Simplifizierte sarcodictyn-derivate als anti-tumor-mittel

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal